Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

TPMeds Secures Tens of Millions in RMB Angel Round Led by Lotus Lake Ventures to Advance TPM004 IND and PepTetris Platform

Fineline Cube Jul 29, 2026
Company Deals

HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases

Fineline Cube Jul 28, 2026
Company Deals

China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio

Fineline Cube Jul 28, 2026
Company Deals Digital

Home Control International Partners with Articura on Localized Healthcare AI Infrastructure in Indonesia

Fineline Cube Jul 27, 2026
Company Deals

Sino Biopharmaceutical and Tempo Scan Form JV to Commercialize Innovative Drugs in Indonesia

Fineline Cube Jul 27, 2026
Policy / Regulatory

China’s CDE Tightens Drug Review Standards with New “No Supplemental Data” Rule for Major Deficiencies

Fineline Cube Jul 29, 2026
Company Drug

Akeso and Allink Biotherapeutics Launch Phase II Trial of PD-1/VEGF-FGFR2b ADC Combination for Squamous NSCLC Following NMPA IND Approval

Fineline Cube Jul 30, 2026
Company Drug

Guangzhou Innogen’s Ultra-Long-Acting GLP-1 Agonist Efsubaglutide Alfa Advances to Adolescent Obesity Phase Ib Trial Following NMPA Approval for Diabetes

Fineline Cube Jul 29, 2026
Company

Sanofi Reports 9.9% Sales Growth to EUR 43.6B, Driven by Dupixent and China

Fineline Cube Jan 30, 2026

Sanofi (NASDAQ: SNY) reported full‑year 2025 revenues of EUR 43.626 billion (USD 47.8 billion), representing 9.9% growth at constant exchange...

Company

Roche Reports 7% Sales Growth to CHF 61.5B, Driven by Pharma and China

Fineline Cube Jan 30, 2026

Roche (SWX: ROG, OTCMKTS: RHHBY) reported full‑year 2025 sales of CHF 61.5 billion : (USD 69.1 billion), representing 7% growth at...

Company Drug

United Labs TUL108 Gets FDA Nod for Antibiotic Resistance Trial

Fineline Cube Jan 29, 2026

United Laboratories International Holdings Ltd (HKG: 3933) announced that the U.S. Food and Drug Administration (FDA)...

Company Deals

Fosun Pharma Licenses HPV DNA Drug VGX-3100 from ApolloBio for Greater China

Fineline Cube Jan 29, 2026

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced a licensing agreement with ApolloBio Corp.,...

Company Deals

Kanghua to Acquire NanoRibo in Phased Deal for mRNA Platform

Fineline Cube Jan 29, 2026

Chengdu Kanghua Biological Products Co., Ltd. (SHE: 300841) announced a plan to increase capital investment...

Company Deals

Lisata Reclaims Certepetide China Rights Amid Kuva Acquisition, CVR Milestone Triggered

Fineline Cube Jan 29, 2026

Lisata Therapeutics announced the termination of its licensing agreement with Qilu Pharmaceutical Co., Ltd. for...

Company Deals

WuXi Biologics Partners with Sinorda on SND006 Bispecific Antibody for Autoimmune Diseases

Fineline Cube Jan 29, 2026

WuXi Biologics (HKG: 2269) announced a collaboration agreement with Guizhou Sinorda Biomedicineic Co., Ltd. to provide...

Company Deals

NeuShen Therapeutics Raises Series A+ for CNS Drug Development

Fineline Cube Jan 29, 2026

NeuShen Therapeutics, a Sino‑US biotech focused on central nervous system (CNS) disorders, announced the completion...

Company Deals

Organon Completes $465M JADA System Sale to Laborie Medical

Fineline Cube Jan 29, 2026

Organon (NYSE: OGN) announced the completed acquisition of its JADA system by Laborie Medical Technologies Corp....

Company Drug

MicuRx MRX-5 Gets FDA Nod for Phase II NTM Lung Disease Study

Fineline Cube Jan 29, 2026

MicuRx Pharmaceuticals Inc., (SHA: 688373) a Sino‑US biopharmaceutical company, announced it has received approval from...

Company Drug

Huiyu Pharma HYP-6589 Gets NMPA Nod for NSCLC Osimertinib Combo

Fineline Cube Jan 29, 2026

Sichuan Huiyu Pharmaceutical Co., Ltd. (SHA: 688553) announced that the National Medical Products Administration (NMPA)...

Company

Servier Oncology Revenue Drives 16% Growth, US Sales Surge 70%

Fineline Cube Jan 29, 2026

Servier announced a 16.2% year‑on‑year (YOY) revenue increase to EUR 6.9 billion (USD 7.52 billion) for the 2024/25 financial...

Company Drug

Changchun High‑Tech’s Firsekibart Filing Accepted for Non‑Infectious Uveitis

Fineline Cube Jan 29, 2026

Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that the National Medical Products...

Company

Danaher Q4 Revenue Grows 3% to $24.6B on Biotech and Diagnostics Innovation

Fineline Cube Jan 29, 2026

Danaher Corporation (NYSE: DHR) reported fourth‑quarter and full‑year 2025 earnings with global revenues rising 3% year‑on‑year...

Company Deals Hospital

Distinct Healthcare IPO Hong Kong: Private Provider Seeks $36M HKEX Listing

Fineline Cube Jan 29, 2026

Distinct Healthcare Holdings Limited, a China‑based private healthcare service provider, released its prospectus this week...

Company

Merck Establishes Chongqing China Branch in Milestone Expansion

Fineline Cube Jan 29, 2026

Merck Sharp & Dohme (MSD, NYSE: MRK), a US‑based biopharmaceutical giant, announced the establishment of a...

Company Deals

Biogen’s Litifilimab Secures FDA Breakthrough Therapy Designation for Lupus

Fineline Cube Jan 29, 2026

Biogen Inc. (NASDAQ: BIIB) announced that its investigational litifilimab has received Breakthrough Therapy Designation (BTD) from...

Company Deals

Seamless Therapeutics Partners with Eli Lilly on $1.12B Hearing Loss Recombinase Deal

Fineline Cube Jan 29, 2026

Seamless Therapeutics, a Germany‑based gene editing company, announced a global strategic research collaboration and license...

Company Drug

Sino Biopharm’s TQA3605 Meets Endpoint in Hepatitis B Phase II Trial

Fineline Cube Jan 28, 2026

Sino Biopharmaceutical Ltd (HKG: 1177) announced that its Category 1 drug TQA3605 has met the primary...

Company Drug

J&J Darzalex Faspro Gets FDA Nod for NDMM D-VRd Regimen

Fineline Cube Jan 28, 2026

Johnson & Johnson (J&J, NYSE: JNJ) announced that the U.S. Food and Drug Administration (FDA) approved...

Posts pagination

1 … 85 86 87 … 701

Recent updates

  • Xgene Pharmaceutical Secures $35M Series D Funding to Advance Non-Opioid Pain Therapy XG005 into Phase III Trials in the US
  • Akeso and Allink Biotherapeutics Launch Phase II Trial of PD-1/VEGF-FGFR2b ADC Combination for Squamous NSCLC Following NMPA IND Approval
  • Guangzhou Innogen’s Ultra-Long-Acting GLP-1 Agonist Efsubaglutide Alfa Advances to Adolescent Obesity Phase Ib Trial Following NMPA Approval for Diabetes
  • GSK Commits £400 Million to Establish Major Cambridge R&D Center, Consolidating UK Research Operations
  • Ribo Life Science’s siRNA Therapy Vortosiran Receives EMA Approval for Stroke Prevention Trial in Atrial Fibrillation Patients
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

Xgene Pharmaceutical Secures $35M Series D Funding to Advance Non-Opioid Pain Therapy XG005 into Phase III Trials in the US

Company Drug

Akeso and Allink Biotherapeutics Launch Phase II Trial of PD-1/VEGF-FGFR2b ADC Combination for Squamous NSCLC Following NMPA IND Approval

Company Drug

Guangzhou Innogen’s Ultra-Long-Acting GLP-1 Agonist Efsubaglutide Alfa Advances to Adolescent Obesity Phase Ib Trial Following NMPA Approval for Diabetes

Company

GSK Commits £400 Million to Establish Major Cambridge R&D Center, Consolidating UK Research Operations

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.